President Donald Trump has signed an executive order to fast-track the approval and research of psychedelic drugs, including psilocybin and ibogaine, for mental health treatments. The order directs the FDA to expedite review processes under the National Priority Voucher program and allow patient access through the Right To Try Act, according to Reason Magazine. This marks a notable policy shift, particularly within the Republican Party.
The directive aims to facilitate faster rescheduling and commercialization of psychedelics, with an emphasis on treating conditions such as PTSD. As reported by Zero Hedge, this announcement led to a surge in stocks of psychedelic companies like Compass Pathways and Atai Beckley, indicating optimistic investor response to an accelerated pathway for these therapies.
Support for the order has come from a spectrum of figures, including conservative lawmakers and public personalities like podcaster Joe Rogan, who was present at the signing, noted by STAT News. NBC News highlighted that the move has gained traction especially among combat veterans and some Republican circles, despite ongoing concerns about the safety profile of these substances.
The order also signals a broader reevaluation of psychedelics by health agencies, as the administration calls for increased access to these drugs and expedited clinical use assessments, according to STAT News and NPR. This could potentially alter existing drug policies and regulatory frameworks that have historically restricted psychedelic research and treatment access.
Looking ahead, attention will focus on how quickly the FDA implements the expedited review process and whether this will lead to new approvals or expanded access programs. Monitoring the safety and efficacy outcomes of these treatments in clinical settings will be critical, alongside legislative developments that could further shape psychedelics policy in the United States.
Ibogaine
Donald Trump
Joe Rogan
